Trending: AbbVie to Buy Cerevel for $45 a Share
Provided by
Dow Jones
9:57 ET--AbbVie is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics for $45 a share, giving the company an equity value of about $8.7 billion. The deal is AbbVie's second major acquisition in the last two weeks, after the pharmaceutical giant said Nov. 30 it would acquire ImmunoGen for $10 billion. Cerevel is developing potential candidates to treat schizophrenia, Parkinson's disease and mood disorders. AbbVie said the deal complements its existing neuroscience portfolio. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
December 07, 2023 10:12 ET (15:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?